Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF

Completed · Phase 4

Conditions studied: Heart Failure, Diastolic, Diastolic Heart Failure, Hypertension

In brief

Unlike heart failure with reduced ejection fraction (HFrEF) where several medicines and devices have been demonstrated to reduce mortality, no such therapies have been identified in HFpEF. This may be in part due to incomplete understanding of the underlying mechanisms of HFpEF. Recently, impaired myocardial blood flow, reduced myocardial energy utilization, and increased myocardial fibrosis have been postulated to play important pathophysiologic roles in HFpEF. The investigators and others have demonstrated that HFrEF may be associated with altered myocardial energy utilization and "energy starvation." However, there are limited data regarding "energy starvation" in HFpEF and the relationships between myocardial blood flow, energy utilization, and fibrosis in HFpEF are largely unknown. Therefore, the purposes of this study are to use non-invasive cardiac imaging techniques to describe cardiac structure, function, blood flow, energetics, and fibrosis, and the relationships between these in order to better understand underlying mechanisms in HFpEF.

Key facts

Study ID

NCT02589977

Run by

Marvin W. Kronenberg, M.D.

People needed

55

Starts

2015-11-01

Expected to finish

2020-01-21

Last updated by the study team

2021-02-02

Who can join

Age: 50 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• estimated glomerular filtration rate (eGFR) > 60 ml/min
• preserved left ventricular ejection fraction (>= 50%) on echocardiography

You may not qualify if…

• coronary artery disease
• diabetes mellitus
• contraindications to cardiac magnetic resonance imaging (CMR)
• weight >350 lbs
• inability to lie flat for imaging
• anemia
• contraindications to regadenoson or aminophylline
• HEALTHY
• Inclusion criteria:
• normal cardiac structure and function on echocardiography
• BP < 140/90
• Exclusion criteria:
• known cardiovascular disease, cardiac risk factors or use of cardiac medications
• HYPERTENSIVE
• Inclusion criteria:
• history of BP >140/90
• 1 or more antihypertensive medications
• LV ejection fraction (LVEF) at least 50%
• current BP < 160/90
• Exclusion criteria:
• known cardiovascular disease or risk factors aside from hypertension or use of cardiac medications
• HFpEF
• Inclusion criteria:
• physician-confirmed diagnosis of HF
• symptomatic HF

Where it is running

• Vanderbilt University Medical Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.